CD226 and Miyoshi myopathy: Analyzing the expression of DNAM-1 on NK cells and their subsets, we show that, compared to treatment in CM, the MFI of this receptor does not change significantly (p > 0.05, Wilcoxon signed rank test) after 18 h in vitro treatments with all investigated cytokines in HC, as well as in MM patients (Figure 4c).